Vaccine responses in newborns
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Immunisation of the newborn represents a key global strategy in overcoming morbidity and mortality due to infection in early life. Potential limitations, however, include poor immunogenicity, safety concerns and the development of tolerogenicity or hypo-responsiveness to either the same antigen and/or concomitant antigens administered at birth or in the subsequent months. Furthermore, the neonatal immunological milieu is polarised towards Th2-type immunity with dampening of Th1-type responses and impaired humoral immunity, resulting in qualitatively and quantitatively poorer antibody responses compared to older infants. Innate immunity also shows functional deficiency in antigen-presenting cells: the expression and signalling of Toll-like receptors undergo maturational changes associated with distinct functional responses. Nevertheless, the effectiveness of BCG, hepatitis B and oral polio vaccines, the only immunisations currently in use in the neonatal period, is proof of concept that vaccines can be successfully administered to the newborn via different routes of delivery to induce a range of protective mechanisms for three different diseases. In this review paper, we discuss the rationale for and challenges to neonatal immunisation, summarising progress made in the field, including lessons learnt from newborn vaccines in the pipeline. Furthermore, we explore important maternal, infant and environmental co-factors that may impede the success of current and future neonatal immunisation strategies. A variety of approaches have been proposed to overcome the inherent regulatory constraints of the newborn innate and adaptive immune system, including alternative routes of delivery, novel vaccine configurations, improved innate receptor agonists and optimised antigen-adjuvant combinations. Crucially, a dual strategy may be employed whereby immunisation at birth is used to prime the immune system in order to improve immunogenicity to subsequent homologous or heterologous boosters in later infancy. Similarly, potent non-specific immunomodulatory effects may be elicited when challenged with unrelated antigens, with the potential to reduce the overall risk of infection and allergic disease in early life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of adaptive immunity by the innate immune system
Iwasaki, A., & Medzhitov, R. (2015) · Nature Immunology · doi:10.1038/ni.3123 · Cited by 2,160 · cited 1×
“The success of neonatal BCG and HBV emphasises that (1) sufficiently robust adaptive immune responses and functional, seroprotective antibody titres can be generated in the newborn period (2) this is will only occur in response to sufficiently potent antigen-adjuvant combinations and/or appropriate cellular interactio…”
Kleinnijenhuis, J., Quintin, J., Preijers, F., Joosten, L. A. B., Ifrim, D. C., Saeed, S., Jacobs, C., van Loenhout, J., de Jong, D., Stunnenberg, H. G., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202870109 · Cited by 1,728 · cited 2×
“As such, Tcell vaccine responsesmay be impacted andmodified by encounters with pathogens from previous infections [71, 73, 74].”
Trunz, B. B., Fine, P., & Dye, C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68507-3 · Cited by 1,114
Towards an understanding of the adjuvant action of aluminium
Marrack, P., McKee, A. S., & Munks, M. W. (2009) · Nature Reviews Immunology · doi:10.1038/nri2510 · Cited by 887 · cited 1×
“Currently alum is the only licenced adjuvant in neonates, despite studies suggesting that it does not promote robust Th1-type immunity [137] .”
B-cell responses to vaccination at the extremes of age
Siegrist, C.-A., & Aspinall, R. (2009) · Nature Reviews Immunology · doi:10.1038/nri2508 · Cited by 659
Innate immune recognition of the microbiota promotes host-microbial symbiosis
Chu, H., & Mazmanian, S. K. (2013) · Nature Immunology · doi:10.1038/ni.2635 · Cited by 630 · cited 1×
“This is illustrated by the finding that germ-free mice are at increased risk for infectious as well as autoimmune disease [2, 130, 131] Currently, the impact of the microbiome on early vaccine responses is still poorly understood.”
Oh, J. Z., Ravindran, R., Chassaing, B., Carvalho, F. A., Maddur, M. S., Bower, M., Hakimpour, P., Gill, K. P., Nakaya, H. I., Yarovinsky, F., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.08.009 · Cited by 541 · cited 1×
“In one study, TLR5-mediated sensing of the microbiota was found to drive lymph node plasma cell differentiation and enhance antibody responses to inactivated polio and influenza vaccines [132].”
Protecting the Newborn and Young Infant from Infectious Diseases: Lessons from Immune Ontogeny
Kollmann, T. R., Kampmann, B., Mazmanian, S. K., Marchant, A., & Levy, O. (2017) · Immunity · doi:10.1016/j.immuni.2017.03.009 · Cited by 478 · cited 17×
“Co-administration of IL12 and influenza subunit vaccine to newborn mice led to increased splenic expression of IFNγ, IL10 and IL15 mRNA and enhanced protective efficacy of antiviral immunisation [139].”
InfluentialSelf-citationStool microbiota and vaccine responses of infants
Huda, M. N., Lewis, Z., Kalanetra, K. M., Rashid, M., Ahmad, S. M., Raqib, R., Qadri, F., Underwood, M. A., Mills, D. A., & Stephensen, C. B. (2014) · PEDIATRICS · doi:10.1542/peds.2013-3937 · Cited by 392
Cumberland, P., Shulman, C. E., Maple, P. A. C., Bulmer, J. N., Dorman, E. K., Kawuondo, K., Marsh, K., & Cutts, F. T. (2007) · The Journal of Infectious Diseases · doi:10.1086/519845 · Cited by 160
Okoko, B. J., Wesumperuma, L. H., Ota, M. O. C., Pinder, M., Banya, W., Gomez, S. F., McAdam, K. P. J., & Hart, A. C. (2001) · The Journal of Infectious Diseases · doi:10.1086/322808 · Cited by 121
Non-specific effects of vaccines: plausible and potentially important, but implications uncertain
Pollard, A. J., Finn, A., & Curtis, N. (2017) · Archives of Disease in Childhood · doi:10.1136/archdischild-2015-310282 · Cited by 118 · cited 1×
“Although theWHO recently recommended that the existing evidencewas insufficient to prompt a revision of immunisation policy, further studies are required to characterise the magnitude, duration and mechanisms of the nonspecific effects of vaccines and, therefore, their potential implications for infant health [65, 66].”
Cited by
Immune determinants of COVID-19 disease presentation and severity
Brodin, P. (2021) · Nature Medicine · doi:10.1038/s41591-020-01202-8 · Cited by 663
Immune system development varies according to age, location, and anemia in African children
Hill, D. L., Carr, E. J., Rutishauser, T., Moncunill, G., Campo, J. J., Innocentin, S., Mpina, M., Nhabomba, A., Tumbo, A., Jairoce, C., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw9522 · Cited by 89
Candidiasis of the Central Nervous System in Neonates and Children With Primary Immunodeficiencies
Drummond, R. A., & Lionakis, M. S. (2018) · Current Fungal Infection Reports · doi:10.1007/s12281-018-0316-y · Cited by 23
Burger, S., Stenger, T., Pierson, M., Sridhar, A., Huggins, M. A., Kucaba, T. A., Griffith, T. S., Hamilton, S. E., & Schuldt, N. J. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2300061 · Cited by 21
Metadata
- Authors
- Saso, A., & Kampmann, B.
- Venue
- Seminars in Immunopathology
- Published
- 2017-11
- Volume
- 39
- Issue
- 6
- Pages
- 627-642
- ISSN
- 1863-2297 (ISSN-L)
- 1863-2300
- OpenAlex
- W2767776597
- Cited by
- 134
- References
- 12
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.